Clinical Trial: Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer (ASpiRE)

U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07002320) titled 'Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer (ASpiRE)' on May 06.

Brief Summary: ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).

Study Start Date: April 28

Study Type: INTERVENTIONAL

Condition: Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Intervention: DRUG: SX-682

SX-682 is supplied as 100mg film coated tablets.

DRUG: Apalutamide

Apalutamide is supplied as 60mg film coated tablets.

Recruitment Status: RECRUITING

Sponsor: Institute of Cancer...